- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Fuji and Olicon strike PACS alliance
Fuji Medical Systems USA and Olicon Imaging Systems this month signed a nonexclusive licensing and product distribution agreement. The deal enables Fuji, which has specialized in the development of computed radiography systems, to sell turnkey PACS
Fuji Medical Systems USA and Olicon Imaging Systems this month signed a nonexclusive licensing and product distribution agreement. The deal enables Fuji, which has specialized in the development of computed radiography systems, to sell turnkey PACS solutions to hospitals.
Under the terms of the agreement, Fuji will distribute Olicon's PACS products when customers desire a single-vendor solution for PACS and CR, according to Clay Larsen, managing director of marketing for Stamford, CT-based Fuji. Fuji can now directly offer its CR customers PACS products, whereas in the past, it had to refer them to another vendor, Larsen said.
San Clemente, CA-based Olicon, on the other hand, will license Fuji's CR image processing algorithms for use on Olicon's workstations, making them more suited for primary CR reading by radiologists, according to Dick Paulsen, Olicon's CEO. Olicon also believes the agreement will give the company an advantage in marketing its products to Fuji CR customers who are interested in upgrading to PACS.
New Study Assesses Long-Term Outcomes of PSMA PET Use in PCa Recurrence Cases
October 24th 2024For patients with biochemical recurrence of prostate cancer, PSMA PET imaging may facilitate a 12.8 percent lower incidence of prostate cancer mortality in contrast to the combination of CT and bone scan, according to long-term outcome estimates from a new decision-analytic modeling study.
Can Diffusion MRI Predict Patient Response to Neoadjuvant Chemotherapy for Breast Cancer?
October 23rd 2024A model emphasizing time-dependent diffusion MRI was 15 percent more effective than apparent diffusion coefficient (ADC) measurements at predicting pathologic complete response to neoadjuvant chemotherapy for women with breast cancer, according to new research.
